姐妹们，最近有一项关于卵巢癌治疗的新研究引起了广泛关注。在刚刚结束的2025 ESGO会议上，意大利TROZZI教授团队公布了一项关于PARP抑制剂（PARPi）维持治疗后铂敏感复发卵巢癌（PSR）患者的研究结果，揭示了PARPi维持治疗的双刃剑效应。这篇文章将为你详细解读这项研究的核心发现，帮助你更好地理解卵巢癌治疗的最新进展。

PARP 抑制剂（PARPi）用于治疗乳腺癌时疗效存在差异，为寻找更好的生物标志物，宾夕法尼亚大学研究人员评估 [18 F]FluorThanatrace（[18 F] FTT）PET 成像。结果显示，基线 [18 F] FTT - PET 摄取及治疗后的变化与无进展生存期相关，这为 PARPi 治疗提供新的生物标志物。

来自国际团队的研究人员揭示了BRCA2缺失导致PARP抑制剂(PARPi)敏感性的分子机制。研究发现BRCA2通过阻止PARP1在DNA损伤位点的异常滞留，保护RAD51丝免受PARPi干扰，阐明了"合成致死"效应的关键环节，为BRCA2突变肿瘤的靶向治疗提供新见解。 肿瘤抑制蛋白BRCA2在DNA同源 ...

与安慰剂相比，所有一线治疗均有明显效果（AA的RR=2.53；ARI的RR=24.25；RR of docetaxel=1.64；RR of Lu177+ARI=33.02；RR of PARPi+ARI=26.47。根据SUCRA值，ARI及其相关 ...

These cancers are, however, quite sensitive to anticancer drugs such as poly (ADP-ribose) polymerase inhibitors (PARPi). When successful, these cancer treatments cause enough DNA damage to trigger ...

These cancers are, however, quite sensitive to anticancer drugs such as poly (ADP-ribose) polymerase inhibitors (PARPi). When successful, these cancer treatments cause enough DNA damage to trigger ...

These cancers are, however, quite sensitive to anticancer drugs such as poly (ADP-ribose) polymerase inhibitors (PARPi). When successful, these cancer treatments cause enough DNA damage to trigger ...

These cancers are, however, quite sensitive to anticancer drugs such as poly (ADP-ribose) polymerase inhibitors (PARPi). When ...

PARPi therapy has been a breakthrough for treating ovarian and breast cancers. In high-income countries, most patients with a ...